Skip to search formSkip to main contentSkip to account menu

pasireotide 40 MG Injection

Known as: PASIREOTIDE 40MG/KIT SA INJ SUSP, PASIREOTIDE 40MG/KIT INJ,SUSP,SA [VA Product], pasireotide LAR 40 MG Injection 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1. Aryl hydrocarbon receptor interacting protein… 
2018
2018
PurposeMedullary thyroid cancer (MTC) is a neuroendocrine tumour of the thyroid C cells. Pasireotide, a multi-receptor targeted… 
2017
2017
Background Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel… 
Review
2016
Review
2016
Pasireotide (Signifor®) long-acting release (LAR) is a next-generation somatostatin receptor ligand (SRL) approved for treatment… 
2016
2016
Abstract Background: Acromegaly is a rare disorder characterized by the over-production of growth hormone (GH). Patients often… 
2015
2015
Objective: A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has… 
2015
2015
PurposePasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind to multiple somatostatin receptor subtypes to mimic… 
Highly Cited
2014
Highly Cited
2014
PurposeA large, randomized, double-blind, Phase III core study demonstrated that pasireotide LAR was significantly superior to… 
2014
2014
241 Background: Pasireotide LAR is a novel somatostatin analog (SSA) with avid binding to somatostatin receptor subtypes (SSTR) 1… 
2011
2011
2040 Background: Patients with recurrent or progressive meningiomas who have exhausted surgical and radiation options have…